AgingResearch.NewsJoin free

HDG1901

Intervention

1 paper studies it2 findings

Across all fields, 1 paper: 1 trial in people

More peptides

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab
  • Human trial1

Outcomes

2

Body weight

downin humans1

1 study

  1. HDG1901 decreases body weight in humans (-4.094kg).

    “At Week 32, the least square mean changes from baseline in bodyweight was -4.094kg for HDG1901 group and -4.346kg for reference semaglutide group.”

    Human trialtype 2 diabetes1mg32 weeksn = 245

    Efficacy and Safety of HDG1901 vs. Ozempic in Patients with Type 2 Diabetes (T2D)—A Randomized, Open-Label, Bioequivalence Phase 3 Trial

    ADA Scientific Sessions 2025 abstract

HbA1c

downin humans1−2%

1 study

  1. HDG1901 decreases HbA1c in humans (-2.047%).

    “The least square mean changes from baseline in the HbA1c at Week 32 was -2.047% for HDG1901 group (N=245) and -2.008% for reference semaglutide group (N=245).”

    Human trialtype 2 diabetes1mg32 weeksn = 245

    Efficacy and Safety of HDG1901 vs. Ozempic in Patients with Type 2 Diabetes (T2D)—A Randomized, Open-Label, Bioequivalence Phase 3 Trial

    ADA Scientific Sessions 2025 abstract

More on HbA1c

Latest

Related